Trulicity (dulaglutide) and Mounjaro (tirzepatide) are prescribed to help manage blood sugar in people with type 2 diabetes. Trulicity also has other uses. Both drugs come as an injection that you ...

Trulicity helps lower blood sugar in adults and children ages 10 years and older with type 2 diabetes. It also may reduce major heart risks in adults with type 2 diabetes who have or are at risk for ...

The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in ...

NEW YORK - Many people looking to lose weight are turning to Ozempic and similar drugs. The issue is that those medicines are also used by people with diabetes. One Long Island man who has Type 2 ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Ozempic is generally more effective in lowering blood sugar and ...

hba1c hemoglobin diabetes test At Week 24, both dulaglutide 0.75mg and 1.5mg added to ongoing SGLT-2 inhibitor therapy showed statistically superior glycemic control (-1.21% and -1.34%, respectively) ...

Below is a comparison of today’s most prescribed GLP-1 medications, including Ozempic and Trulicity, both widely used for ...

Some of the Trulicity app’s features include medication reminders, a virtual demo of the Trulicity pen, live chats to answer questions in real-time, videos, and access to a savings card. To have a ...

Mounjaro (tirzepatide) and Trulicity (dulaglutide) are prescription medications that help manage blood sugar levels in adults with type 2 diabetes. Though they work in slightly different ways, they ...

Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine. A common ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

Eli Lilly has put the flesh on the bones of its REWIND cardiovascular outcomes study for diabetes drug Trulicity, a key element in its defence against a rival drug from Novo Nordisk. All told, there ...